Symposium | Practical management of adverse events with immunotherapies

During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, US, delivered a presentation on the practical management of adverse events with immunotherapies in multiple myeloma.

Sergio Giralt provided an overview of the safety of bispecific antibodies in multiple myeloma, highlighting the common long-term effects associated with B-cell maturation antigen and G-protein coupled receptor family C group 5 member D targets (Figures 1 and 2). Then, Giralt shared recommendations for the management of late and delayed toxicities, including prophylactic and monitoring strategies.

Figure 1. Rationale for GPRC5D as a therapeutic target in MM* 

BMSC, Bone marrow stromal cells; DARA, daratumumab; GPRC5D, G protein-coupled receptor class C group 5 member D; HD, human donor; HLA, human leukocyte antigen; MM, multiple myeloma; PD, programmed death; POM, pomalidomide.
*Adapted from Smith, et al.¹

Figure 2. Long-term effects of bispecific antibodies* 

BCMA, B-cell maturation antigen; CHIP, clonal hematopoiesis of indeterminate potential; CMV, cytomegalovirus; GPRC5D; G protein-coupled receptor class C group 5; HHV6, human herpesvirus 6; MDS, myelodysplastic syndrome; PCP, Pneumocystis pneumonia.
*Provided by Sergio Giralt.

This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.